InsiderTrades

Form 4 for MIST Milestone Pharmaceuticals Inc.

Accepted 2022-09-09 00:00:00 ET · period of report 2022-09-07 · accession 0000902664-22-004219 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
I 2022-09-09 2022-09-07 MIST RTW INVESTMENTS, LP 10% P - Purchase $8.71 +1.56M 4.32M +56% +$13.56M
I 2022-09-09 2022-09-07 MIST RTW INVESTMENTS, LP 10% S - Sale $8.71 -1.56M 4.32M -27% -$13.56M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Shares, no par value ("Common Shares") 2022-09-07 P A 1,557,346 $8.71 4,315,102 I See footnote — — (F1) Ordinary course rebalancing transactions in which certain RTW Funds (as defined below) rebalance holdings of the Issuer among the RTW Funds. After the transactions reported herein, the amount of Common Shares of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change. (F2) This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to Common Shares held by certain investment funds managed by the Adviser (the "RTW Funds"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser.
2 Common Common Shares 2022-09-07 S D 1,557,346 $8.71 4,315,102 I See footnote — — (F1) Ordinary course rebalancing transactions in which certain RTW Funds (as defined below) rebalance holdings of the Issuer among the RTW Funds. After the transactions reported herein, the amount of Common Shares of the Issuer beneficially owned in the aggregate by the Reporting Persons did not change. (F2) This Form 4 is being filed by each of (i) RTW Investments, LP (the "Adviser") with respect to Common Shares held by certain investment funds managed by the Adviser (the "RTW Funds"), and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of the Adviser.